14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BIS vs REW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
REW Overall Winner
6-Pillar Tally: BIS 0 – 0 REW (6 Tie)
Matrix Metrics: BIS 2 – 1 REW
As of Nov 16, 2026, Proshares UltraShort Technology (REW) is the stronger overall head-to-head candidate over ProShares UltraShort NASDAQ Biotechnology (BIS) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BIS carries a Unified Composite Score of 54.1/100 (HOLD) at $11.11 (N/M Forward P/E, N/A operating margin), whereas REW carries 34.3/100 (SELL) at $13.99 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While BIS currently prints a higher short-term Unified Composite Score (54.1/100 HOLD vs. REW 34.3/100 SELL), REW captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIS vs REW. Trailing 12-month operating profitability (BIS N/A vs REW N/A) and valuation multiples (BIS N/M vs REW N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BIS vs REW Key Questions & Quantitative Answers
As of Nov 16, 2026, Proshares UltraShort Technology (REW) is the stronger overall head-to-head candidate over ProShares UltraShort NASDAQ Biotechnology (BIS) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BIS carries a Unified Composite Score of 54.1/100 (HOLD) at $11.11 (N/M Forward P/E, N/A operating margin), whereas REW carries 34.3/100 (SELL) at $13.99 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BIS currently prints a higher short-term Unified Composite Score (54.1/100 HOLD vs. REW 34.3/100 SELL), REW captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
BIS and REW split Growth & Scale metrics: BIS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with REW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BIS generates N/A in USD-normalized revenue versus N/A for REW. In operating R&D and SG&A reinvestment, BIS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REW.
BIS and REW trade at balanced relative valuation multiples. BIS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIS (N/A ROE) versus REW (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BIS carries 70.9% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.39β · 60% Vol realized risk). By comparison, REW carries 144.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-3.36β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.